Takeda Pharmaceutical Co Ltd (TKPHF) Other Accumulated Expenses (2017 - 2026)

Takeda Pharmaceutical's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.6 billion for Q2 2026.

• In Q2 2026, Other Accumulated Expenses changed 0.5% year-over-year to $3.6 billion; the TTM figure through Jun 2026 stood at $3.6 billion (changed 0.5% YoY), while the FY2026 annual figure was $3.9 billion, changed 0.15% from the prior year.
• Other Accumulated Expenses for Q2 2026 stood at $3.6 billion, down from $3.8 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $5.0 billion in Q1 2022, with the low at $3.3 billion in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $3.9 billion (2023), against an average of $4.0 billion.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses declined 16.13% in 2024, then climbed 2.51% in 2025.
• Takeda Pharmaceutical's Other Accumulated Expenses stood at $4.5 billion in 2022, then slipped by 12.6% to $4.0 billion in 2023, then declined by 5.98% to $3.7 billion in 2024, then fell by 0.87% to $3.7 billion in 2025, then slipped by 2.69% to $3.6 billion in 2026.
• Business Quant data shows TKPHF's Other Accumulated Expenses at $3.6 billion in Q2 2026, $3.8 billion in Q1 2026, and $3.7 billion in Q4 2025.